The FDA told Amgen to test whether a quarter-dose of sotorasib worked as well as the amount on the label. It did, but the biotech is sticking to the higher dose, which earns it an extra $180,000 a ...
Swiss drugmaker Sandoz launched its biosimilar Hyrimoz with the same prices as Boehringer and Amgen, whose Amjevita was the first Humira biosimilar to hit the U.S. market, priced at a 5% and 55% ...
Just last week, Tesla laid off yet another round of workers. This time, however, Tesla gutted an entire team. Around 500 ...
In recent years, Amgen has been using acquisitions as a way to bolster its competitive position. And that's the big unknown for investors going forward: whether its recent purchases will pay off.
As with Epogen, the initial discoveries that laid the basis for the drug had ... That decade of investment and research was paying off. In 1992, Amgen hit the billion dollars sales mark and ...
Amgen's acquisition of Horizon Therapeutics has made it a major player in the rare disease space, with potential for long-term shareholder return. The company has key pipeline milestones in 2024 ...
Chroma Medicine laid off an undisclosed number of employees ... Sandoz reached an agreement with Amgen to resolve all patent ...
Stocks Rally As Jobs Report Rekindles Rate Cut Hopes, Apple Rockets, Bitcoin Soars Above $61,000: What's Driving Markets Friday? A weaker-than-expected jobs report sparked a widespread market ...
In its opening months, after spinning off as a separate business from Novartis, Sandoz is riding the wave of a strong launch of its biosimilar version of AbbVie’s Humira (adalimumab). | After spinning ...
April 4 (Reuters) - Boehringer Ingelheim on Thursday said it will lay off some of its salesforce due ... with the same prices as Boehringer and Amgen, whose Amjevita was the first Humira ...